Soterix Medical

Soterix Medical operates at the intersection of research-grade neuromodulation equipment and clinical brain-stimulation systems. Its portfolio spans 1x1 and high-definition tDCS/tES, neurotargeting software, remotely supervised stimulation, EEG-linked platforms, TMS, focused ultrasound, and multimodal monitoring. That breadth gives it a different profile from larger diversified medical-device companies such as Medtronic, Abbott, Boston Scientific, and LivaNova, whose neuromodulation businesses generally emphasize established therapeutic franchises and larger-scale commercialization. Soterix Medical is more specialized in configurable stimulation, experimental protocols, and research workflows, while the 2026 SPRY clearance indicates movement into a regulated clinical indication. Its potential differentiator is the combination of stimulation hardware, planning software, subject-specific targeting, and integrated EEG, fNIRS, PET, or fMRI workflows. The company’s New York base, approximately 11-50 employee range, and $3.41 million in disclosed grant funding suggest a focused specialist rather than a scaled enterprise incumbent.

Soterix Medical’s trajectory shows a gradual expansion from research-oriented electrical stimulation into integrated monitoring and clinical treatment. The company was founded in 2010, and its earliest identified grant was $2.5 million in 2016. A further $910,000 National Institute of Mental Health grant in 2022 brought disclosed cumulative funding to $3.41 million across two rounds, with grants rather than conventional venture financing driving the visible capital history. Product development broadened in April 2024 with the MxN-GO EEG System, a wire-free platform combining EEG and electrical stimulation for mobile research. The next major inflection point came on Mar 5, 2026, when SPRY TMS received clearance for major depressive disorder treatment in adults who had not responded to prior antidepressants. That clearance creates a path from institutional research tools toward clinical deployment, though public information does not provide revenue, commercial adoption, regulatory pipeline, or employee-growth figures. The current product range, including REMOTE neuromodulation, HD-tES, neurotargeting software, MEGA-TMS, and multimodal platforms, supports a strategy of serving multiple stages of the neuroscience workflow rather than relying on a single device category.